Skip to content

Study · Animal study (in vivo) · mouse and rat · 1999

9 results

Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.

Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, Seiwerth S, Mise S, Turkovic B, Dodig G, Miklic P, Buljat G, Prkacin I

European journal of pharmacology1 Aug 1999Cited by 46 (Europe PMC)

PMID10499368 (opens in a new tab)DOI10.1016/s0014-2999(99)00486-0 (opens in a new tab)PepBankPUB-10499368
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, BPC‑157 given with haloperidol markedly attenuated catalepsy.

    In plain wordsIn mice, BPC‑157 given with haloperidol clearly reduced catalepsy.

    Peptide
    BPC-157
    Outcome
    DecreaseHaloperidol-induced catalepsy in mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Prominent catalepsy, otherwise consistently seen in the mice treated with haloperidol (0.625, 1.25, 2.5, 5.0 and 10.0 mg/kg b.w., i.p.) and fluphenazine (0.3125, 0.625, 1.25, 2.5 and 5.0 mg/kg b.w., i.p.) after 1.5, 3, 4.5, 6 and 7.5 h following administration, was markedly attenuated when pentadeca…
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, BPC‑157 given with fluphenazine markedly attenuated catalepsy.

    In plain wordsIn mice, BPC‑157 given with fluphenazine clearly reduced catalepsy.

    Peptide
    BPC-157
    Outcome
    DecreaseFluphenazine-induced catalepsy in mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Prominent catalepsy, otherwise consistently seen in the mice treated with haloperidol (0.625, 1.25, 2.5, 5.0 and 10.0 mg/kg b.w., i.p.) and fluphenazine (0.3125, 0.625, 1.25, 2.5 and 5.0 mg/kg b.w., i.p.) after 1.5, 3, 4.5, 6 and 7.5 h following administration, was markedly attenuated when pentadeca…
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice given a neuroleptic, the number of cataleptic mice was markedly lower with BPC‑157 throughout most of the experimental period.

    In plain wordsIn mice given a neuroleptic, fewer mice showed catalepsy when BPC‑157 was also given.

    Peptide
    BPC-157
    Outcome
    DecreaseNumber of cataleptic mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The number of cataleptic mice was markedly lower throughout most of the experimental period.
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice given lower neuroleptic doses, BPC‑157 postponed the appearance of catalepsy, especially at the higher BPC‑157 dose.

    In plain wordsIn mice given lower neuroleptic doses, BPC‑157 delayed the start of catalepsy.

    Peptide
    BPC-157
    Outcome
    IncreaseOnset of catalepsy at lower neuroleptic doses
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, on challenge with lower doses of neuroleptics, catalepsy appearance was postponed and the mice, otherwise cataleptic since the earliest period, became cataleptic later, not before 3 or 4.5 h after neuroleptic administration, especially if protected with higher pentadecapeptide dose.
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice challenged with haloperidol or fluphenazine, BPC‑157 reduced somatosensory disorientation.

    In plain wordsIn mice given haloperidol or fluphenazine, BPC‑157 reduced disorientation.

    Peptide
    BPC-157
    Outcome
    DecreaseSomatosensory disorientation in haloperidol- or fluphenazine-challenged mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    reduced not only catalepsy but somatosensory disorientation (for 7.5 h after administration of a neuroleptic, assessed at intervals of 1.5 h, by a simple scoring system [0-5]) in haloperidol- or fluphenazine-challenged mice
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice treated with sulpiride or clozapine, where catalepsy was absent, BPC‑157 reduced somatosensory disorientation.

    In plain wordsIn mice given sulpiride or clozapine, BPC‑157 reduced disorientation.

    Peptide
    BPC-157
    Outcome
    DecreaseSomatosensory disorientation in sulpiride- or clozapine-treated mice
    Study

    mousen: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    reduced not only catalepsy but somatosensory disorientation (for 7.5 h after administration of a neuroleptic, assessed at intervals of 1.5 h, by a simple scoring system [0-5]) in haloperidol- or fluphenazine-challenged mice as it did in mice treated with sulpiride (20, 40, 80 and 160 mg/kg b.w., i.p…
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 given with haloperidol completely inhibited the gastric lesions that regularly occurred after haloperidol in control rats.

    In plain wordsIn rats, BPC‑157 given with haloperidol completely prevented the stomach lesions seen in control rats.

    Peptide
    BPC-157
    Outcome
    DecreaseHaloperidol-induced gastric lesions in rats
    Study

    ratn: not reported in source

    Comparator
    Control rats given haloperidol
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg, 10 ng, 1.0 ng or 100 pg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Coadministration of pentadecapeptide BPC 157 (10 microg, 10 ng, 1.0 ng, 100 pg/kg b.w., i.p.) to rats completely inhibited the lesions otherwise regularly evident 24 h after haloperidol (5.0 mg/kg b.w., i.p.) in control rats (18 of 20 rats had gastric lesions).
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the 10 microg and 10 ng BPC‑157 regimens antagonized haloperidol catalepsy.

    In plain wordsIn rats, BPC‑157 at the two higher doses reduced haloperidol-induced catalepsy.

    Peptide
    BPC-157
    Outcome
    DecreaseHaloperidol catalepsy in rats (higher doses)
    Study

    ratn: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    This activity accompanied the antagonism of the haloperidol catalepsy in rats (assessed at 60-min intervals from I to 5 h after haloperidol), when 10-microg- or 10-ng regimens were given
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats, lower BPC‑157 doses could not influence haloperidol catalepsy.

    In plain wordsIn rats, lower BPC‑157 doses did not change haloperidol-induced catalepsy.

    Peptide
    BPC-157
    Outcome
    No significant changeHaloperidol catalepsy in rats (lower doses)
    Study

    ratn: not reported in source

    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    10 µg/kg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    (lower doses could not influence catalepsy).
    1 context sentence
    Summary · context
    Consequently, whether pentadecapeptide BPC 157, that by itself has no cataleptogenic effect in normal animals, may attenuate the immediate effects of neuroleptics application, particularly catalepsy, was the focus of the present report.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.